Recent advances in the treatment of tuberculosis

被引：11
|
作者：
Motta, Ilaria [1 ]
Boeree, Martin [2 ,3 ]
Chesov, Dumitru [4 ,5 ,6 ]
Dheda, Keertan [7 ,8 ,9 ,10 ,11 ]
Gunther, Gunar [12 ,13 ]
Horsburgh Jr, Charles Robert [14 ,15 ,16 ]
Kherabi, Yousra [17 ]
Lange, Christoph [6 ,18 ,19 ,20 ]
Lienhardt, Christian [21 ,22 ]
McIlleron, Helen M. [23 ,24 ]
Paton, Nicholas I. [22 ,25 ]
Stagg, Helen R. [26 ]
Thwaites, Guy [27 ,28 ]
Udwadia, Zarir [29 ]
Van Crevel, Reinout [2 ,3 ,28 ]
Velasquez, Gustavo E. [30 ,31 ]
Wilkinson, Robert J. [32 ,33 ]
Guglielmetti, Lorenzo [34 ,35 ]
机构：
[1] Med Sans Frontieres, Manson Unit, London, England
[2] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Radboud Ctr Infect Dis, Med Ctr, Nijmegen, Netherlands
[4] Chiril Draganiuc Phthisiopneumol Inst, Kishinev, Moldova
[5] Nicolae Testemitanu State Univ Med & Pharm, Dept Pulmonol & Allergol, Kishinev, Moldova
[6] Res Ctr Borstel, Div Clin Infect Dis, Borstel, Germany
[7] Univ Cape Town, Ctr Lung Infect & Immun, Dept Med, Div Pulmonol, Cape Town, South Africa
[8] Univ Cape Town, UCT Lung Inst, Cape Town, South Africa
[9] Univ Cape Town, South African MRC UCT Ctr Study Antimicrobial Resi, Cape Town, South Africa
[10] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa
[11] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Immunol & Infect, London, England
[12] Bern Univ Hosp, Dept Pulmonol & Allergol, Inselspital, Bern, Switzerland
[13] Univ Namibia, Fac Hlth Sci, Dept Med Sci, Windhoek, Namibia
[14] Boston Univ, Dept Epidemiol, Boston, MA USA
[15] Boston Univ, Dept Biostat, Boston, MA USA
[16] Boston Univ, Dept Global Hlth & Med, Boston, MA USA
[17] Bichat Claude Bernard Hosp, Assistance Publ Hop Paris, Infect & Trop Dis Dept, Paris, France
[18] Univ Lubeck, German Ctr Infect Res DZIF, Resp Med & Int Hlth, Lubeck, Germany
[19] Univ Lubeck, Dept Int Hlth Infect Dis, Lubeck, Germany
[20] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat Global Immigrant, Houston, TX USA
[21] Inst Rech Dev, Dept Translat Res Appl HIV & Infect Dis, Montpellier, France
[22] London Sch Hyg & Trop Med, Dept Infect Dis, London, England
[23] Univ Cape Town, Dept Med, Div Clin Pharmacol, Cape Town, South Africa
[24] Univ Cape Town, Inst Infect Dis & Mol Med, Wellcome Ctr Infect Dis Res Africa CIDRI Africa, Cape Town, South Africa
[25] Natl Univ Singapore, Dept Med, Singapore, Singapore
[26] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England
[27] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam
[28] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England
[29] Hinduja Hosp & Res Ctr, Dept Internal Med & Pulmonol, Mumbai, India
[30] Univ Calif San Francisco, UCSF Ctr TB, San Francisco, CA USA
[31] Univ Calif San Francisco, Div HIV Infect Dis & Global Med, San Francisco, CA USA
[32] Francis Crick Inst, London, England
[33] Imperial Coll London, Dept Infect Dis, London, England
[34] Sorbonne Univ, Ctr Immunol & Malad Infect CIMI Paris, INSERM, U1135, Paris, France
[35] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Lab Bacteriol Hyg,Ctr Natl Reference Mycobacteries, Paris, France
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2024年 / 30卷 / 09期
基金：
英国医学研究理事会; 美国国家卫生研究院; 英国惠康基金;
关键词：
Clinical trial; Directed therapy; Dose; Host; Isoniazid resistance; MDR-TB; Mycobacterium tuberculosis; New drugs; Optimization; Pharmacogenomics; Pharmacokinetics; Pre-XDR TB; MULTIDRUG-RESISTANT TUBERCULOSIS; DRUG-RESISTANT; PHASE-II; MOXIFLOXACIN; REGIMENS; TRIAL; GATIFLOXACIN; RIFAPENTINE; PRETOMANID; OPTIMIZE;
D O I：
10.1016/j.cmi.2023.07.013
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Background: Tuberculosis (TB) is a global health challenge and one of the leading causes of death worldwide. In the last decade, the TB treatment landscape has dramatically changed. After long years of stagnation, new compounds entered the market (bedaquiline, delamanid, and pretomanid) and phase III clinical trials have shown promising results towards shortening duration of treatment for both drug-susceptible (Study 31/A5349, TRUNCATE-TB, and SHINE) and drug-resistant TB (STREAM, NiX-TB, ZeNix, and TB-PRACTECAL). Dose optimization of rifamycins and repurposed drugs has also brought hopes of further development of safe and effective regimens. Consequently, international and WHO clinical guidelines have been updated multiple times in the last years to keep pace with these advances. Objectives: This narrative review aims to summarize the state-of-the-art on treatment of drug-susceptible and drug-resistant TB, as well as recent trial results and an overview of ongoing clinical trials. Sources: A non-systematic literature review was conducted in PubMed and MEDLINE, focusing on the treatment of TB. Ongoing clinical trials were listed according to the authors' knowledge and completed consulting clinicaltrials.gov and other publicly available websites (www.resisttb.org/clinical-trials-progress-report, www.newtbdrugs.org/pipeline/trials). Content: This review summarizes the recent, major changes in the landscape for drug-susceptible and drug-resistant treatment, with a specific focus on their potential impact on patient outcomes and programmatic TB management. Moreover, insights in host-directed therapies, and advances in pharmacokinetics and pharmacogenomics are discussed. A thorough outline of ongoing therapeutic clinical trials is presented, highlighting different approaches and goals in current TB clinical research. (c) 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：1107 / 1114
页数：8
相关论文
共 50 条
12345